AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 181 min read$KMTS

Webster Brian Daniel sold $412K of KMTS

Webster Brian Daniel (See Remarks) sold 15,000 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at $27.48 ($0.41M total) on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Webster Brian Daniel
Published Aug 18, 2026, 11:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 11:14 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$KMTS
Neutral
high confidence
Mentioned
$KMTS
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The disclosed open-market sale reduces insider holdings but, due to the stated 10b5-1 pre-arranged plan, it is typically treated as lower-signal than discretionary selling.

02

Market read

Traders may briefly reassess sentiment around KMTS, but the event is primarily administrative and not a new business catalyst.

03

What to watch

The filing does not disclose any new KMTS fundamentals; the only actionable element is monitoring for future non-10b5-1 insider transactions.

Relevance 3/10Novelty 2/10Timing: filed 2026-08-18, sale dated 2026-08-17

Background

This is an SEC Form 4 insider transaction disclosure for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS).

Company-level read

Ticker impact

$KMTSNeutralHigh confidence
Context

Form 4 shows officer/director Webster Brian Daniel sold 15,000 KMTS shares at $27.4787 on 2026-08-17 under a 10b5-1 plan.

Expected impact

Low near-term impact; any effect is likely sentiment-only and quickly absorbed.

Evidence & confidence

The filing is a scheduled open-market sale under a pre-arranged 10b5-1 plan, with no accompanying company-specific operational or financial disclosure.

Market effects

Sector

No clear sector read-through from a single 10b5-1 sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations, so traders may ignore it.

Key entities

  • issuer
    KMTS

    Kestra Medical Technologies, Ltd., the company whose insider sale is disclosed.

  • insider
    Webster Brian Daniel

    Officer and director who sold 15,000 shares via an open-market transaction under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KMTS insider trading history →

Related articles

JUL 16
$KMTSMedAI 8/10

Kestra Medical Technologies Q4 Earnings Call Highlights

Kestra Medical Technologies (NASDAQ:KMTS) reported a Q4 GAAP net loss of $38.8 million and adjusted EBITDA loss of $26.7 million. CFO Vaseem Mahboob said gross margin should rise steadily and reiterated confidence in gross margins above 70% over the next few years. The company guided FY2027 revenue to $137 million, up 44% from FY2026, and added a $200 million term loan facility.

yahoo.com6 min
JUL 15
$KMTSMed

Kestra Secures $200M Non-Dilutive Financial To Strengthen Balance Sheet And Fuel Growth

Kestra Medical Technologies (KMTS) said it secured a five-year, up to $200M non-dilutive term loan facility managed by Pharmakon Advisors. A $75M tranche closed, retiring part of its $45M loan and covering fees. Remaining tranches total $125M with revenue and acquisition conditions. The loan has 48 months interest-only at 3-month SOFR plus 5.5% (3.25% floor).

rttnews.com4 min
JUL 15
$KMTSMed

Kestra Medical Technologies Ltd (KMTS) Q4 2026 Earnings Call Highlights: Record Revenue

Kestra Medical Technologies (KMTS) reported Q4 2026 call highlights. CFO Vaseem Mahboob said fiscal 2027 guidance targets $137 million revenue, driven by prescription volume growth, in-network mix, revenue cycle management improvements, and field expansion, with 44% growth. CEO Brian Webster discussed WCD guideline support, share gains, adding ~40 reps, and refinancing to cut cost of capital by 24% while keeping an M&A option open.

yahoo.com4 min
JUL 15
$KMTSMed

Kestra Medical (KMTS) Q4 2026 Earnings Call Transcript

Kestra Medical (KMTS) discussed its FY26 results on an earnings call. Revenue was $95 million for the year, up 59% from FY25, and $28.6 million in Q4, up 66% year over year. Gross margin rose to 51.4% for FY26 (up about 11 pts). The company reported 6.3k prescriptions and expanding sales territories to about 130.

yahoo.com7 min
JUL 14
$KMTSMedAI 8/10

Kestra Medical Technologies Secures Up to $200 Million of Non-Dilutive Financing

Kestra Medical Technologies (Nasdaq: KMTS) announced a five-year, non-dilutive term loan facility managed by Pharmakon Advisors. It includes $75M funded at closing (used to retire a $45M loan plus fees), $25M available through July 2027, $50M through June 2028 subject to $150M trailing revenue, and a $50M acquisition tranche. Interest is SOFR plus 5.5% with a 3.25% floor; Kestra reported $262M cash/investments as of Apr. 30, 2026.

manilatimes.net4 min